Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

IGFBP-3 nuclear localization predicts human prostate cancer recurrence.

Seligson DB, Yu H, Tze S, Said J, Pantuck AJ, Cohen P, Lee KW.

Horm Cancer. 2013 Feb;4(1):12-23. doi: 10.1007/s12672-012-0124-8. Epub 2012 Sep 26.

3.

Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study.

Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM, Marcelli M.

J Urol. 1998 Jun;159(6):2220-5.

PMID:
9598573
4.

SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.

Bauman TM, Becka AJ, Sehgal PD, Huang W, Ricke WA.

Hum Pathol. 2015 Nov;46(11):1744-51. doi: 10.1016/j.humpath.2015.07.015. Epub 2015 Jul 29.

5.

Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy.

Izumi K, Li Y, Zheng Y, Gordetsky J, Yao JL, Miyamoto H.

Hum Pathol. 2012 Nov;43(11):1991-2000. doi: 10.1016/j.humpath.2012.02.008. Epub 2012 May 21.

PMID:
22617231
6.

Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.

Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G.

Urol Oncol. 2014 May;32(4):426-32. doi: 10.1016/j.urolonc.2013.09.006. Epub 2013 Dec 12.

PMID:
24332637
7.

Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.

Zeng X, Hu Z, Wang Z, Tao J, Lu T, Yang C, Lee B, Ye Z.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):119-25. doi: 10.1038/pcan.2013.51. Epub 2014 Jan 14.

8.

Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.

Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Boström PJ, Alanen K, Nurmi M, Nees M, Härkönen P.

Int J Cancer. 2016 Jul 1;139(1):140-52. doi: 10.1002/ijc.30048. Epub 2016 Mar 12.

10.

Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.

Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K.

Eur Urol. 2007 May;51(5):1259-66. Epub 2006 Jun 14.

PMID:
16806661
11.

Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.

Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL.

Int J Cancer. 2005 Jan 20;113(3):415-22.

12.

Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading.

Terracciano D, Bruzzese D, Ferro M, Mazzarella C, Di Lorenzo G, Altieri V, Mariano A, Macchia V, Di Carlo A.

Prostate. 2012 Jan;72(1):100-7. doi: 10.1002/pros.21411. Epub 2011 Apr 25.

PMID:
21520165
13.
14.

Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1.

Degeorges A, Wang F, Frierson HF Jr, Seth A, Chung LW, Sikes RA.

Cancer Res. 1999 Jun 15;59(12):2787-90.

15.

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV.

Clin Cancer Res. 2003 Dec 15;9(17):6357-62.

16.

Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.

Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, Bégin LR, Mes-Masson AM, Saad F.

BJU Int. 2008 May;101(10):1302-9. doi: 10.1111/j.1464-410X.2008.07514.x. Epub 2008 Feb 21.

17.

CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.

Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW.

J Urol. 1998 Aug;160(2):459-65.

PMID:
9679898
18.

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.

Gannon PO, Lessard L, Stevens LM, Forest V, Bégin LR, Minner S, Tennstedt P, Schlomm T, Mes-Masson AM, Saad F.

Eur J Cancer. 2013 Jul;49(10):2441-8. doi: 10.1016/j.ejca.2013.02.026. Epub 2013 Mar 28.

PMID:
23541563
19.

Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.

Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, Sagalowsky AI, McConnell JD, Marston W, Leach FS.

Cancer. 2002 Feb 1;94(3):690-9. Erratum in: Cancer 2002 May 15;94(10):2800.

20.

Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.

Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Bostwick DG.

J Urol. 1999 Apr;161(4):1229-32.

PMID:
10081875

Supplemental Content

Support Center